NIH, GreenLight Biosciences to collaborate on COVID-19 vaccine development for new variants

NIH, GreenLight Biosciences to collaborate on COVID-19 vaccine development for new variants

 

GreenLight Biosciences has announced a collaboration with the National Institutes of Health (NIH) to develop COVID-19 vaccines that are more broadly protective against new variants and with longer-lasting effects.

 

"This is a tremendous opportunity for us to partner with a premier vaccine discovery team and use our mRNA platform to accelerate the development of coronavirus vaccines which are more broadly protective and durable than those currently available," says Amin Khan, PhD, GreenLight's Chief Science Officer, Human Health.

 

GreenLight—in collaboration with the Vaccine Research Center (VRC), part of NIH's National Institute of Allergy and Infectious Diseases—will co-design and test mRNA vaccines against coronaviruses with the goal of developing vaccines that confer a more durable immune response than current vaccines. In addition, they will work together to develop systems that expedite new designs into clinical use.

 

SARS-CoV-2, the virus that causes COVID-19, continues to evolve and accumulate genomic mutations with the potential to negatively affect the efficacy of existing medical countermeasures. For the current COVID-19 pandemic and future coronavirus-related pandemics, the rapid development and deployment of vaccines active against a range of coronaviruses, including variants of SARS-CoV-2, will be vital for public health.

 

According to the NIH, cooperative research and development agreements, or CRADAs , "provide an exciting opportunity for NIH investigators to join with their colleagues from industry and academia in the joint pursuit of common research goals. Government scientists serve the larger mission of NIH, to facilitate the development and commercialization of health-care pharmaceuticals and products. Companies also can leverage their own R&D efforts while collaborating in state-of-the-art NIH research."

 

  About GreenLight Biosciences  
GreenLight Biosciences aims to address some of the world's biggest problems by delivering on the full potential of RNA for human health and agriculture. Our RNA platform allows us to research, design, and manufacture for human, animal, and plant health. In human health, this includes messenger RNA vaccines and therapeutics. In agriculture, this includes RNA to protect honeybees and a range of crops. The company's platform is protected by numerous patents. GreenLight's human health product candidates are in the pre-clinical stage, and its product candidates for the agriculture market are in the early stages of development or regulatory review. GreenLight is a public benefit corporation that trades under the ticker GRNA on Nasdaq. For more information, visit   https://www.greenlightbiosciences.com/   

 

  Contact  
David Pesci
Head of Media Relations
GreenLight Biosciences
dpesci@greenlightbio.com  
For press, email: press@greenlightbio.com  
For investors, email: investors@greenlightbio.com  

 

  Notes to editors  

 
  1. GreenLight has been developing a Covid vaccine before this announcement. Further details can be found here:   https://www.greenlightbiosciences.com/greenlight-envi-and-iavi-begin-work-on-omicron-variant-adapted-covid-19-vaccine-candidate/   
  2.  
  3. GreenLight is designing three messenger RNA products, including a vaccine for shingles with Serum Institute of India (SII), the world's biggest vaccine producer. SII also has an option to expand the relationship further for two additional vaccine or therapeutic targets.   https://greenlightbiosciences.com/greenlight-biosciences-holdings-pbc-grna-enters-into-multitarget-licensing-agreement-with-serum-institute-of-india-to-develop-and-commercialize-messenger-rna-products-for-emerging-markets-globally/   
  4.  
  5. GreenLight's Human Health Advisory Board includes Barney Graham, named one of the Heroes of the Year in 2021 by Time magazine for his role in developing the COVID-19 vaccine:   https://www.greenlightbiosciences.com/co-developer-of-covid-19-vaccine-joins-greenlight-advisory-board/   
  6.  

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/826c004a-589b-4c5e-bc03-136ffec49bec  

 

 

 

  Primary Logo 

 

News Provided by GlobeNewswire via QuoteMedia

GRNA
The Conversation (0)
GreenLight Biosciences Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress

GreenLight Biosciences Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress

 
  • Working toward clinical trial initiation for COVID vaccine candidate in 2023
  •  
  • Shingles vaccine candidate selection planned for 2023 in partnership with Serum Institute of India
  •  
  • Calantha™, Colorado potato beetle solution, commercial launch planned for 2023, subject to regulatory approval
  •  
  • Honeybee solution EPA submission planned for 2023
  •  
  • Strategic realignment focused on near-term value drivers.
  •  

GreenLight Biosciences Holdings, PBC (Nasdaq:GRNA), a public benefit corporation striving to bring effective and safe solutions to make food clean and affordable for everyone and dedicated to developing health solutions for every person on our planet, today reported operational highlights and financial results for the third quarter ended September 30, 2022.

 

"We continue to make progress against our key goals, which include obtaining proof-of-concept for our mRNA platform in human health and progressing late-stage plant health programs toward commercialization. This quarter we carried out a strategic realignment to better optimize our R&D efforts and prioritize our nearer-term value drivers. These efficiencies, combined with our August financing, will help us navigate today's challenging market conditions," said Andrey Zarur, CEO of GreenLight. "In 2023, pending EPA approval, we anticipate bringing Calantha™, the first-ever foliar-applied RNA solution for crop protection, to market and submitting a regulatory application for our honeybee solution. In addition, we are pursuing potential opportunities to enable us to initiate clinical trials for our COVID-19 vaccine candidate and continuing to work with Serum Institute of India (SII) on identifying and developing a shingles vaccine candidate."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
GreenLight Biosciences to Participate in Upcoming Investor Conferences in November

GreenLight Biosciences to Participate in Upcoming Investor Conferences in November

 

GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the potential of RNA to address some of the world's toughest problems in human health and agriculture, today announced that Dr. Andrey Zarur, CEO, and Susan Keefe, CFO will participate in two upcoming investor conferences in November.

 

  Credit Suisse 31   st   Annual Healthcare Conference  
Date: Tuesday, November 8, 2022
Location: Rancho Palos Verdes, CA – GreenLight to participate virtually  

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
GreenLight Biosciences announces realignment to focus on near-term value drivers

GreenLight Biosciences announces realignment to focus on near-term value drivers

 

GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to bring effective and safe solutions to make food clean and affordable for everyone and dedicated to developing health solutions for every person on our planet, today announced a realignment to focus on key near-term value drivers and extend its cash runway.

 

Key changes include further optimizing GreenLight's organizational structure to better serve the company's operations and more efficiently support the research, development and commercialization of its plant health and human health pipelines, primarily by integrating GreenLight's platform team into the respective teams for human health and plant health. These integrations come with a staff reduction of approximately 25%.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
GreenLight Biosciences and Queensland University of Technology partner to tackle destructive fall armyworm using RNA

GreenLight Biosciences and Queensland University of Technology partner to tackle destructive fall armyworm using RNA

 
  •   GreenLight Biosciences and Queensland University of Technology (QUT) partner to create a solution for fall armyworm
     
  •  
  •   Fall armyworm is one of the most destructive insect pests on the planet, causing   more than US$2 billion in annual   crop loss worldwide

     
  •  
  •   The Australian government has been searching for a more environmentally-friendly solution to fall armyworm and is supporting the partnership with a AUD$400,000 grant  
  •  

Researchers from Boston's GreenLight Biosciences and the Queensland University of Technology (QUT) in Brisbane, Australia, have announced an agreement to develop a solution to fall armyworm, which causes more than US$2 billion in annual global crop loss.

 

The partnership includes an Australian government grant to QUT of more than AUD$400,000 from the Australian Research Council. It brings together the teams of two preeminent researchers, Dr. Julia Bally and Professor Peter Waterhouse from the QUT   Centre for Agriculture and the Bioeconomy   , and GreenLight's Plant Health research and development team.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
GreenLight Biosciences Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

GreenLight Biosciences Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

 

GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to bring effective and safe solutions to make food clean and affordable for everyone and dedicated to developing health solutions for every person in our planet, today reported operational highlights and financial results for the second quarter ended June 30, 2022.

 

"GreenLight's RNA platform has continued to prove its value for developing a wide range of solutions to feeding the world and keeping it healthy. We founded GreenLight to change the world, and we have continued to make progress this quarter," said Andrey Zarur, CEO of GreenLight. "Today, we are pleased to announce a capital infusion of $108.4 million. We are grateful for the support, continued faith, and trust of our longtime investors. We also welcome new investors who have decided to join GreenLight in our mission to help feed the world and keep it healthy. This will allow us to continue to make progress across our pipeline.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare.

But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no indication that US hospitals are stockpiling equipment ahead of expected price hikes, according to recent findings from GlobalData.

Keep reading...Show less
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This establishes the timeline for the planned safety and efficacy futility interim analysis by an independent Data Monitoring Committee (DMC).

Keep reading...Show less
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less
Zoono Group

Exclusive UK Packaging Agreement signed between Sharpak Aylesham Limited, Zoono, and OSY

Zoono Group Limited (Company) (ASX: ZNO) is pleased to update the market on an exclusive contract signed with Sharpak Aylesham Limited (Sharpak) and the Company’s partner in the food supply chain sector, OSY Group Limited (OSY).

Keep reading...Show less

Latest Press Releases

Related News

×